Haleon Buys Back Shares for £9.8M
Ticker: HLNCF · Form: 6-K · Filed: Sep 12, 2025 · CIK: 1900304
Sentiment: neutral
Topics: share-repurchase, buyback, capital-return
TL;DR
Haleon just bought back 1.2M shares for nearly £10M. Buyback continues.
AI Summary
Haleon plc announced on September 12, 2025, that it repurchased 1,200,000 of its own ordinary shares at an average price of £8.2039 per share. The total cost of these repurchases amounted to £9,844,680. These shares were bought on the London Stock Exchange as part of its share buyback program.
Why It Matters
This share repurchase indicates Haleon's commitment to returning capital to shareholders and can signal management's confidence in the company's valuation.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of share repurchases, which is a common corporate action.
Key Numbers
- 1,200,000 — Shares Repurchased (Part of ongoing buyback program)
- £9.8M — Total Cost (Amount spent on share repurchases)
Key Players & Entities
- Haleon plc (company) — Registrant
- 1,200,000 (dollar_amount) — Number of shares repurchased
- £8.2039 (dollar_amount) — Average price per share
- £9,844,680 (dollar_amount) — Total cost of repurchases
- September 12, 2025 (date) — Date of transaction
FAQ
What was the total number of Haleon plc ordinary shares repurchased on September 12, 2025?
Haleon plc repurchased 1,200,000 ordinary shares.
What was the average price paid per share for the repurchased shares?
The average price paid per share was £8.2039.
What was the total amount spent on the share repurchase on September 12, 2025?
The total cost of the repurchases was £9,844,680.
Where did the share repurchases take place?
The repurchases were made on the London Stock Exchange.
Is this share repurchase part of a larger program?
Yes, the filing indicates this is a 'Transaction in Own Shares', implying it's part of an ongoing share buyback initiative.
Filing Stats: 572 words · 2 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-12 06:44:18
Filing Documents
- a0423z.htm (6-K) — 34KB
- a0423z000.jpg (GRAPHIC) — 3KB
- 0001654954-25-010678.txt ( ) — 39KB
From the Filing
IN OWN SHARES a0423z   UNITED STATES   SECURITIES AND EXCHANGE COMMISSION   Washington, D.C. 20549     FORM 6-K   REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934   For the month of September 2025   Commission File Number: 001-41411   Haleon plc (Translation of registrant’s name into English)   Building 5, First Floor, The Heights, Weybridge, Surrey, KT13 0NY (Address of principal executive offices)     Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:     Form 20-F ☒   Form 40-F ☐       EXHIBIT INDEX   Exhibit Number Description 99.1 12 September 2025 - “Transaction in Own Shares”     99.1       Haleon plc:   Transaction in own shares   12 September 2025:   Haleon plc (the "Company" or "Haleon") today announces   the purchase of 273,737 ordinary shares of £0.01 each in the Company (the "Shares") for cancellation   under the second tranche of its share buyback programme announced on 31 July 2025.     London Stock Exchange CBOE (UK)/BXE CBOE (UK)/CXE Date of purchase: 11 September 2025 11 September 2025 11 September 2025 Number of Shares purchased: 273,737 - - Highest price paid per Share (p): 366.0000 - - Lowest price paid per Share (p): 362.0000 - - Volume weighted average price paid per Share (p): 364.1267 - -   Following the settlement of the above, the Company's registered share capital   is 8,952,377,436 ordinary shares of £0.01 each, of which 1,527,758 are held as treasury shares.   Therefore, the number of ordinary shares with voting rights is 8,950,849,678 and   this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.   In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:   http://www.rns-pdf.londonstockexchange.com/rns/0419Z_1-2025-9-11.pdf   This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.   This announcement and individual trade breakdown will also be available on the Company's website at:   www.haleon.com/investors .   Enquiries     Investors Media   Jo Russell   +44 7787 392441 Zoë   Bird +44 7736 746167 Rakesh Patel      +44 7552 484646 Victoria Durman +44 7894 505730 Email:   investor-relations@haleon.com Email:   corporate.media@haleon.com   About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as  Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu  and  Voltaren  - are built on trusted science, innovation and deep human understanding.   For more information, please visit   www.haleon.com .        SIGNATURE       Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.       HALEON PLC (Registrant)   Date: September 12, 2025 By: /s/ Amanda Mellor     Name: Amanda Mellor     Title: Company Secretary